Lundbeck starts new study of tablet version of drug
A new phase I study will investigate how a Lundbeck drug is absorbed by the body when administered in tablet form as opposed to capsule form, which is being trialled within a number of indications.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT
Drug candidate LU AG06466 is the focus of yet another clinical trial for which Lundbeck is currently recruiting patients.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
No room for more mistakes at Lundbeck
For subscribers
Lundbeck introduces vaccine requirement for US staff
For subscribers
.jpg&w=384&q=75)
